Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02559206 · ClinicalTrials.gov registry record · Phase 2
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 759
- Enrollment target
NCT02559206 is a Phase 2 study that has completed, run by Ironwood Pharmaceuticals. The registered enrollment target is 759 participants.
The verdict
NCT02559206, a Phase 2 study, has completed, sponsored by Ironwood Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 759 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety, efficacy, and dose response of two delayed release formulations of linaclotide (DR; DR formulation 1 is DR1; DR formulation 2 is DR2) administered orally to patients with irritable bowel syndrome with constipation (IBS-C). Additional objectives include understanding how the two DR formulations compare with each other and with the FDA-approved 290 μg LINZESS® (the immediate release \[IR\] formulation of linaclotide).
Interventions
- DRUG Matching Placebo
- DRUG Linaclotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 759 participants |
| Start Date | 2015-10-22 |
| Est. Completion | 2016-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02559206
The ClinicalTrials.gov registry entry for NCT02559206 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 759 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironwood Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02559206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02559206 about?
NCT02559206 is a clinical study titled "Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)". The objectives of this study are to evaluate the safety, efficacy, and dose response of two delayed release formulations of linaclotide (DR; DR formulation 1 is DR1; DR formulation 2 is DR2) administered orally to patients with irritable bowel syndrome with constipation (IBS-C). Additional objective...
What is the current status of trial NCT02559206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 759 participants. The study started on 2015-10-22. Estimated completion is 2016-09-30.
What interventions are being tested in trial NCT02559206?
The interventions under investigation include: Matching Placebo (DRUG), Linaclotide (DRUG).
Who is sponsoring clinical trial NCT02559206?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.